AI ANTIBODY DESIGN
Improve the quality of your desired leads faster and more
Design, not Discovery
Shorten your drug discovery steps and make the research process more agile. Using Silica Corpora's Platform, your Drug Discovery process and preclinical stages can be accelerated by a factor of 15, redefining your Value Chain.
Discover why Silica Corpora is your best ally for antibody discovery
Powering Antibody Discovery with AI
Acting as a Contract Research Organization, Silica Corpora aims to help Small-Medium Enterprises (SMEs) to improve accuracy in the Drug Discovery process by reducing the number of Antibodies to be tested experimentally in the pre-clinical trial phase.
From historical data to Valuable Assets
We use accumulated data on previously completed or failed projects to re-train our AI models to improve the quality of drug candidates in the future projects.
Boost accuracy without altering the process
Besides the higher accuracy of the NLP-inspired approach, our technology doesn’t disrupt existing in vitro workflows of our customers, thus, our methods can be easily plugged into established business processes with no need for new equipment, expertise, or personnel.
WHY SILICA CORPORA
A vanguardistic approach to reach the next generation of drug development.
Taking advantage of the progress in natural language processing (NLP) methods, we work only with AA sequences instead of 3D structures. Using trained AI models on amino acid sequences we can generate more quality Antibodies from scratch, without using In Vitro nor In Vivo Methods.